Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development

Bibliography

• Badimon JJ, Fuster V, Chesebro JH, Badimon L: Coronary atherosclerosis. A multifactorial disease. Circulation 87, II3–II16 (1993).
   Google Scholar
• Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88, 1785–1792 (1991).
   Google Scholar
• ▪ Good review on oxidzied lipoporteins in atherosclerosis.
   Google Scholar
• Vaya J, Aviram M, Mahmood S, Hayek T, Grenadir E, Hoffman A, Milo S: Selective distribution of oxysterols in atherosclerotic lesions and human plasma lipoproteins. Free Radic. Res. 34, 485–497 (2001).
   Google Scholar
• Carpenter KL, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ: Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochim. Biophys. Acta 1256, 141–150 (1995).
   Google Scholar
• Mackness B, Hunt R, Durrington PN, Mackness MI: Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A‑I in the human artery wall with the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17, 1233–1238 (1997).
   Google Scholar
• Aviram M: Antioxidants in restenosis and atherosclerosis. Curr. Int. Cardiol. Rep. 1, 66–78 (1999).
   Google Scholar
• Marsillach J, Mackness M, Fransec R, Beltran R, Joven J, Camp J: Immunohistochemical analysis of paraoxonase‑1,2 and 3 in human atheroma plaques. Presented at: 3rd International Conference on Paraoxnases 2008. Los Angeles, CA, USA, 7–10 September 2008.
   Google Scholar
• Primo‑Parmo SL, Sorenson RC, Teiber J, La Du BN: The human serum paraoxonase/ arylesterase gene (PON1) is one member of a multigene family. Genomics 33, 498–507 (1996).
   Google Scholar
• Aviram M, Rosenblat M: Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr. Opin. Lipidol. 16, 393–399 (2005).
   Google Scholar
• ▪▪ Good review of paraoxonase and cardiovascular disease, covering its nutritional and pharmacological influences.
   Google Scholar
• Khatib S, Musa R, Vaya J: An exogenous marker: a novel approach for the characterization of oxidative stress. Bioorg. Med. Chem. 15, 3661–3666 (2007).
   Google Scholar
• Tavori H, Aviram M, Khatib S et al.: Human carotid atherosclerotic plaque increases oxidative state of macrophages and low‑density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects. Free Radic. Biol. Med. 46, 607–615 (2009).
   Google Scholar
• Aviram M, Hardak E, Vaya J et al.: Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase‑like activities. Circulation 101, 2510–2517 (2000).
   Google Scholar
• Gallicchio L, Boyd K, Matanoski G et al.: Carotenoids and the risk of developing lung cancer: a systematic review. Am. J. Clin. Nutr. 88, 372–383 (2008).
   Google Scholar
• Li WF, Sun CW, Cheng TJ, Chang KH, Chen CJ, Wang SL: Risk of carotid atherosclerosis is associated with low serum paraoxonase (PON1) activity among arsenic exposed residents in Southwestern Taiwan. Toxicol. Appl. Pharmacol. 236, 246–253 (2009).
   Google Scholar
• Ibanez B, Vilahur G, Badimon JJ: Plaque progression and regression in atherothrombosis. J. Thromb. Haemost. 5(Suppl. 1), 292–299 (2007).
   Google Scholar
• Williams KJ, Feig JE, Fisher EA: Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat. Clin. Pract. Cardiovasc. Med. 5, 91–102 (2008).
   Google Scholar
• Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M: Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1‑knockout mice. Free Radic. Biol. Med. 34, 774–784 (2003).
   Google Scholar
• Shih DM, Gu L, Xia YR et al.: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284–287 (1998).
   Google Scholar
• ▪ Along with [23], demonstrates a good presentation of the antiatherogenic properties of paroxoase 1 (PON1).
   Google Scholar
• Rozenberg O, Shih DM, Aviram M: Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181, 9–18 (2005).
   Google Scholar
• Adachi J, Asano M, Naito T, Ueno Y, Tatsuno Y: Chemiluminescent determination of cholesterol hydroperoxides in human erythrocyte membrane. Lipids 33, 1235–1240 (1998).
   Google Scholar
• Billecke S, Draganov D, Counsell R et al.: Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28, 1335–1342 (2000).
   Google Scholar
• ▪ Along with [71], this article is of major importance for the understanding of PON1 substrate specificity.
   Google Scholar
• Draganov DI, La Du BN: Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch. Pharmacol. 369, 78–88 (2004).
   Google Scholar
• Jakubowski H, Zhang L, Bardeguez A, Aviv A: Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ. Res. 87, 45–51 (2000).
   Google Scholar
• ▪▪ Along with [18], demonstrates a good presentation of the antiatherogenic properties of PON1.
   Google Scholar
• Teiber JF, Draganov DI, La Du BN: Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol. 66, 887–896 (2003).
   Google Scholar
• Watson AD, Berliner JA, Hama SY et al.: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96, 2882–2891 (1995).
   Google Scholar
• Rosenblat M, Gaidukov L, Khersonsky O et al.: The catalytic histidine dyad of high density lipoprotein‑associated serum paraoxonase‑1 (PON1) is essential for PON1‑mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281, 7657–7665 (2006).
   Google Scholar
• Aviram M: Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic. Res. 33(Suppl.), S85–S97 (2000).
   Google Scholar
• Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo‑Parmo SL, La Du BN: Paraoxonase inhibits high‑density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101, 1581–1590 (1998).
   Google Scholar
• Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7, 69–76 (1996).
   Google Scholar
• Ahmed Z, Ravandi A, Maguire GF et al.: Multiple substrates for paraoxonase‑1 during oxidation of phosphatidylcholine by peroxynitrite. Biochem. Biophys. Res. Commun. 290, 391–396 (2002).
   Google Scholar
• Aviram M, Billecke S, Sorenson R et al.: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18, 1617–1624 (1998).
   Google Scholar
• Nishio E, Watanabe Y: Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme’s free thiols. Biochem. Biophys. Res. Commun. 236, 289–293 (1997).
   Google Scholar
• Rozenberg O, Aviram M: S‑glutathionylation regulates HDL‑associated paraoxonase 1 (PON1) activity. Biochem. Biophys. Res. Commun. 351, 492–498 (2006).
   Google Scholar
• Teiber JF, Billecke SS, La Du BN, Draganov DI: Estrogen esters as substrates for human paraoxonases. Arch. Biochem. Biophys. 461, 24–29 (2007).
   Google Scholar
• Santanam N, Parthasarathy S: Aspirin is a substrate for paraoxonase‑like activity: implications in atherosclerosis. Atherosclerosis 191, 272–275 (2007).
   Google Scholar
• Fuhrman B, Gantman A, Aviram M: Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR‑BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis 211(1), 61–68 (2010).
   Google Scholar
• Aronis A, Aharoni‑Simon M, Madar Z, Tirosh O: Triacylglycerol‑induced impairment in mitochondrial biogenesis and function in J774.2 and mouse peritoneal macrophage foam cells. Arch. Biochem. Biophys. 492, 74–81 (2009).
   Google Scholar
• Tavori H, Khatib S, Aviram M, Vaya J: Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity. Bioorg. Med. Chem. 16, 7504–7509 (2008).
   Google Scholar
• Draganov DI: Lactonases with oragnophosphatase activity: structural and evolutionary perspectives. Chem. Biol. Interact. 187(1‑3), 370–372 (2010).
   Google Scholar
• Tavori H, Vaya J, Aviram M: Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity. Adv. Exp. Med. Biol. 660, 99–111 (2010).
   Google Scholar
• Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN: Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid. Res. 46, 1239–1247 (2005).
   Google Scholar
• Proudfoot JM, Barden AE, Loke WM, Croft KD, Puddey IB, Mori TA: HDL is the major lipoprotein carrier of plasma F2‑isoprostanes. J. Lipid. Res. 50, 716–722 (2009).
   Google Scholar
• Karabina SA, Lehner AN, Frank E, Parthasarathy S, Santanam N: Oxidative inactivation of paraoxonase – implications in diabetes mellitus and atherosclerosis. Biochim. Biophys. Acta. 1725, 213–221 (2005).
   Google Scholar
• Mackness MI, Mackness B, Durrington PN: Paraoxonase and coronary heart disease. Atheroscler. Suppl. 3, 49–55 (2002).
   Google Scholar
• Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K: Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with Type 2 diabetes. Metabolism 49, 1400–1405 (2000).
   Google Scholar
• Dantoine TF, Debord J, Charmes JP et al.: Decrease of serum paraoxonase activity in chronic renal failure. J. Am. Soc. Nephrol. 9, 2082–2088 (1998).
   Google Scholar
• Tanimoto N, Kumon Y, Suehiro T et al.: Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 72, 2877–2885 (2003).
   Google Scholar
• Costa LG, Vitalone A, Cole TB, Furlong CE: Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 69, 541–550 (2005).
   Google Scholar
• Nguyen SD, Hung ND, Cheon‑Ho P, Ree KM, Dai‑Eun S: Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochim. Biophys. Acta. 1790, 155–160 (2009).
   Google Scholar
• Jaouad L, de Guise C, Berrougui H et al.: Age‑related decrease in high‑density lipoproteins antioxidant activity is due to an alteration in the PON1’s free sulfhydryl groups. Atherosclerosis 185, 191–200 (2006).
   Google Scholar
• Aviram M, Rosenblat M, Billecke S et al.: Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26, 892–904 (1999).
   Google Scholar
• Franco‑Pons N, Marsillach J, Joven J, Camps J, Closa D: Serum paraoxonase undergoes inhibition and proteolysis during experimental acute pancreatitis. J. Gastrointest. Surg. 12, 891–899 (2008).
   Google Scholar
• Feingold KR, Memon RA, Moser AH, Grunfeld C: Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139, 307–315 (1998).
   Google Scholar
• Efrat M, Rosenblat M, Mahmood S, Vaya J, Aviram M: Di‑oleoyl phosphatidylcholine (PC‑18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies. Atherosclerosis 202, 461–469 (2009).
   Google Scholar
• Nguyen SD, Sok DE: Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. Biochem. J. 375, 275–285 (2003).
   Google Scholar
• Nguyen SD, Sok DE: Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids. J. Lipid Res. 45, 2211–2220 (2004).
   Google Scholar
• Fuhrman B, Volkova N, Aviram M: Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low‑density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis 161, 307–316 (2002).
   Google Scholar
• Rosenblat M, Draganov D, Watson CE, Bisgaier CL, La Du BN, Aviram M: Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23, 468–474 (2003).
   Google Scholar
• Efrat M, Aviram M: Macrophage paraoxonase 1 (PON1) binding sites. Biochem. Biophys. Res. Commun. 376, 105–110 (2008).
   Google Scholar
• Coleman R, Hayek T, Keidar S, Aviram M: A mouse model for human atherosclerosis: long‑term histopathological study of lesion development in the aortic arch of apolipoprotein E‑deficient (E0) mice. Acta Histochem. 108, 415–424 (2006).
   Google Scholar
• Rosenblat M, Vaya J, Shih D, Aviram M: Paraoxonase 1 (PON1) enhances HDLmediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179, 69–77 (2005).
   Google Scholar
• Rosenblat M, Oren R, Aviram M: Lysophosphatidylcholine (LPC) attenuates macrophage‑mediated oxidation of LDL. Biochem. Biophys. Res. Commun. 344, 1271–1277 (2006).
   Google Scholar
• Horke S, Witte I, Wilgenbus P, Kruger M, Strand D, Forstermann U: Paraoxonase‑2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stressinduced caspase activation. Circulation 115, 2055–2064 (2007).
   Google Scholar
• Ng CJ, Wadleigh DJ, Gangopadhyay A et al.: Paraoxonase‑2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell‑mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276, 44444–44449 (2001).
   Google Scholar
• Aviram M, Rosenblat M: Oxidative Stress in Cardiovascular Disease: Role of Oxidized Lipoproteins in Macrophage Foam Cell Formation in Atherosclerosis. Marcel Dekker, NY, USA, 557–590 (2004).
   Google Scholar
• Rozenberg O, Shih DM, Aviram M: Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase‑A2‑like activity and lysophosphatidylcholine formation. Arterioscler. Thromb. Vasc. Biol. 23, 461–467 (2003).
   Google Scholar
• Fuhrman B, Shiner M, Volkova N, Aviram M: Cell‑induced copper ion‑mediated low density lipoprotein oxidation increases during in vivo monocyte‑to‑macrophage differentiation. Free Radic. Biol. Med. 37, 259–271 (2004).
   Google Scholar
• Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125–1131 (2002).
   Google Scholar
• Jessup W, Gelissen IC, Gaus K, Kritharides L: Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr. Opin. Lipidol. 17, 247–257 (2006).
   Google Scholar
• Gaidukov L, Tawfik DS: High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with apoA‑I. Biochemistry 44, 11843–11854 (2005).
   Google Scholar
• Harel M, Aharoni A, Gaidukov L et al.: Structure and evolution of the serum paraoxonase family of detoxifying and anti‑atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11, 412–419 (2004).
   Google Scholar
• ▪▪ Along with [21], this article is of major importance for the understanding of PON1 substrate specificity.
   Google Scholar
• Gaidukov L, Rosenblat M, Aviram M, Tawfik DS: The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J. Lipid Res. 47, 2492–2502 (2006).
   Google Scholar
• Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161, 1–16 (2002).
   Google Scholar
• Nofer JR, Levkau B, Wolinska I et al.: Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL‑associated lysosphingolipids. J. Biol. Chem. 276, 34480–34485 (2001).
   Google Scholar